News
23andMe sale reveals what your genetic data is worth. It’s less than you think
The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK made a $300 million dollar deal with 23andMe which allowed it to acquire the genetic data of 5 million people. That means the value of each customer’s data was about $60 at that time.
Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...
Republican Sen. John Cornyn and Democratic Sen. Amy Klobuchar are rolling out a measure to protect sensitive genetic data ...
Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...
Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...
The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data ...
Missouri Attorney General Andrew Bailey is alerting residents after biotechnology company 23andMe filed for bankruptcy in March.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback